Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Bempedoic Acid vs Evolocumab (Repatha): Evolocumab (Repatha) has the stronger overall evidence (4.5 vs 4.3/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Evolocumab (Repatha) wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Bempedoic Acid and Evolocumab (Repatha) have evidence — compare verdict strength side-by-side.
180 mg orally once daily, with or without food, under a clinician. Available alone (Nexletol) or co-formulated with ezetimibe 10 mg (Nexlizet). A prescription drug — dosing is set by a prescriber.
any
Oral tablet (bempedoic acid 180 mg)
Standard approved dosing is 140 mg subcutaneously every 2 weeks OR 420 mg subcutaneously once monthly, under a clinician. A prescription drug; this is informational, not a recommendation.
any
Subcutaneous prefilled autoinjector (evolocumab)
Weeks (full effect by ~12 weeks)
Months to years
Throughout use
Weeks to months
Weeks
Months to years
Weeks
Throughout use
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
The New England journal of medicine (2023) · Rct · n=13970
CLEAR Outcomes: ~13,970 statin-intolerant patients randomized to bempedoic acid 180 mg vs placebo
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
The New England journal of medicine (2019) · Rct · n=2230
CLEAR Harmony: 2,230 patients with ASCVD and/or familial hypercholesterolemia on maximally tolerated statins
Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
JAMA (2019) · Rct · n=779
CLEAR Wisdom: 779 high-cardiovascular-risk patients on maximally tolerated statins
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
The New England journal of medicine (2017) · Rct · n=27564
FOURIER randomized ~27,564 patients with atherosclerotic cardiovascular disease on statin therapy
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.
Circulation (2022) · Open label
FOURIER-OLE: open-label extension following patients on long-term evolocumab
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
JAMA (2016) · Rct
GLAGOV randomized statin-treated patients to evolocumab or placebo with serial intravascular ultrasound
Evolocumab (Repatha) has a higher evidence score (4.5/10 vs 4.3/10) and wins in 1 of 3 categories.
For support heart health, Evolocumab (Repatha) has a higher relevance score (80 vs 72).
No known interactions between Bempedoic Acid and Evolocumab (Repatha) have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.